CY1105108T1 - Θepαπευτικοι συνδυασμοι που πepιλαμβανουν αμλοδιπινη και ατορβαστατινη - Google Patents
Θepαπευτικοι συνδυασμοι που πepιλαμβανουν αμλοδιπινη και ατορβαστατινηInfo
- Publication number
- CY1105108T1 CY1105108T1 CY20061101012T CY061101012T CY1105108T1 CY 1105108 T1 CY1105108 T1 CY 1105108T1 CY 20061101012 T CY20061101012 T CY 20061101012T CY 061101012 T CY061101012 T CY 061101012T CY 1105108 T1 CY1105108 T1 CY 1105108T1
- Authority
- CY
- Cyprus
- Prior art keywords
- atorvastatin
- combinations
- amlodipine
- hyperlipidemia
- atherosclerosis
- Prior art date
Links
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 title abstract 3
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 title abstract 3
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 title abstract 3
- 229960000528 amlodipine Drugs 0.000 title abstract 3
- 229960005370 atorvastatin Drugs 0.000 title abstract 3
- 230000001225 therapeutic effect Effects 0.000 title 1
- 206010002383 Angina Pectoris Diseases 0.000 abstract 2
- 201000001320 Atherosclerosis Diseases 0.000 abstract 2
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract 2
- 206010020772 Hypertension Diseases 0.000 abstract 2
- 230000000747 cardiac effect Effects 0.000 abstract 2
- 230000001747 exhibiting effect Effects 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 208000024891 symptom Diseases 0.000 abstract 2
- 239000011885 synergistic combination Substances 0.000 abstract 2
- 239000002253 acid Substances 0.000 abstract 1
- 239000000654 additive Substances 0.000 abstract 1
- 230000000996 additive effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Microbiology (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Η παρούσα εφεύρεση σχετίζεται με τους φαρμακευτικούς συνδυασμούς της αμλοδιπίνης ή ενός φαρμακευτικώς αποδεκτού άλατος προσθήκης οξέων εξ αυτής και της ατορβαστατίνης ή ενός φαρμακευτικώς αποδεκτού άλατος εξ αυτής, με τις τυποποιημένες συσκευασίες που περιέχουν τους συνδυασμούς αυτού του είδους και τις μεθόδους χρήσης των συνδυασμών αυτού του είδους για την θεραπεία υποκειμένων που πάσχουν από στηθάγχη, αθηροσκλήρυνση, συνδυασμένη υπέρταση και υπερλιπιδαιμία και για την θεραπεία υποκειμένων που εμφανίζουν συμπτώματα καρδιακού κινδύνου, συμπεριλαμβανομένων των ανθρώπων. Αυτή η εφεύρεση σχετίζεται επίσης με τους προσθετικούς και συνεργιστικούς συνδυασμούς αμλοδιπίνης και ατορβαστατίνης όπου εκείνοι οι συνεργιστικοί συνδυασμοί είναι χρήσιμοι για την θεραπεία των υποκειμένων που πάσχουν από στηθάγχη, αθηροσκλήρυνση, συνδυασμένη υπέρταση και υπερλιπιδαιμία και των υποκειμένων που εμφανίζουν συμπτώματα καρδιακού κινδύνου, συμπεριλαμβανομένων των ανθρώπων.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US5727597P | 1997-08-29 | 1997-08-29 | |
EP98936587A EP1003503B1 (en) | 1997-08-29 | 1998-08-11 | Therapeutic combinations comprising amlodipin and atorvastatin |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1105108T1 true CY1105108T1 (el) | 2010-03-03 |
Family
ID=22009597
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20061101012T CY1105108T1 (el) | 1997-08-29 | 2006-07-21 | Θepαπευτικοι συνδυασμοι που πepιλαμβανουν αμλοδιπινη και ατορβαστατινη |
CY200700003C CY2007003I1 (el) | 1997-08-29 | 2007-01-25 | Θepαπευτικοι συνδυασμοι που πepιλαμβανουν αμλοδιπινη και ατορβαστατινη |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY200700003C CY2007003I1 (el) | 1997-08-29 | 2007-01-25 | Θepαπευτικοι συνδυασμοι που πepιλαμβανουν αμλοδιπινη και ατορβαστατινη |
Country Status (49)
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6262277B1 (en) | 1994-09-13 | 2001-07-17 | G.D. Searle And Company | Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake |
US6642268B2 (en) * | 1994-09-13 | 2003-11-04 | G.D. Searle & Co. | Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors |
UA53716C2 (uk) | 1997-06-25 | 2003-02-17 | Пфайзер Продактс Інк. | Тартратна сіль заміщеного дипептиду, спосіб її одержання, проміжні сполуки та спосіб їх одержання, фармацевтична композиція (варіанти), спосіб підвищення рівнів ендогенного гормону росту та спосіб лікування або профілактики захворювань (варіанти) |
GT199800127A (es) * | 1997-08-29 | 2000-02-01 | Combinaciones terapeuticas. | |
US7129265B2 (en) | 1999-04-23 | 2006-10-31 | Mason R Preston | Synergistic effects of amlodipine and atorvastatin metabolite as a basis for combination therapy |
SK15382001A3 (sk) * | 1999-04-23 | 2002-05-09 | R. Preston Mason | Farmaceutický prostriedok obsahujúci amlodipín, spôsob liečenia a spôsob znižovania krvného tlaku |
CA2375372C (en) * | 1999-05-27 | 2007-01-09 | George Chang | Mutual prodrugs of amlodipine and atorvastatin |
HN2000000050A (es) | 1999-05-27 | 2001-02-02 | Pfizer Prod Inc | Sal mutua de amlodipino y atorvastatina |
CA2314517A1 (en) | 1999-07-26 | 2001-01-26 | Gust H. Bardy | System and method for determining a reference baseline of individual patient status for use in an automated collection and analysis patient care system |
CN1378547A (zh) | 1999-10-11 | 2002-11-06 | 辉瑞大药厂 | 用作磷酸二酯酶抑制剂的5-(2-取代的-5-杂环基磺酰基吡啶-3-基)-二氢吡唑并[4,3-d]嘧啶-7-酮类化合物 |
US6336903B1 (en) | 1999-11-16 | 2002-01-08 | Cardiac Intelligence Corp. | Automated collection and analysis patient care system and method for diagnosing and monitoring congestive heart failure and outcomes thereof |
US20050119270A1 (en) * | 2000-08-04 | 2005-06-02 | Mason R. P. | Synergistic effect of amlodipine and atorvastatin on aortic endothelial cell nitric oxide release |
WO2002011723A1 (en) * | 2000-08-04 | 2002-02-14 | Mason R Preston | Synergistic effect of amlodipine and atorvastatin |
AU2001284413A1 (en) * | 2000-08-30 | 2002-03-13 | Sankyo Company Limited | Medicinal compositions for preventing or treating heart failure |
GB0027410D0 (en) * | 2000-11-09 | 2000-12-27 | Pfizer Ltd | Mutual prodrug of amlodipine and atorvastatin |
US6737430B2 (en) | 2000-11-09 | 2004-05-18 | Pfizer, Inc. | Mutual prodrug of amlodipine and atorvastatin |
PE20030324A1 (es) * | 2001-07-31 | 2003-04-03 | Warner Lambert Co | Composiciones farmaceuticas de amlodipina y atorvastatina |
US20030044459A1 (en) * | 2001-09-04 | 2003-03-06 | Pfizer Inc. | Biomodulated multiparticulate formulations |
US7670612B2 (en) | 2002-04-10 | 2010-03-02 | Innercap Technologies, Inc. | Multi-phase, multi-compartment capsular delivery apparatus and methods for using same |
US20040053842A1 (en) * | 2002-07-02 | 2004-03-18 | Pfizer Inc. | Methods of treatment with CETP inhibitors and antihypertensive agents |
US7071210B2 (en) * | 2002-07-02 | 2006-07-04 | Pfizer Inc. | CETP inhibitors in combination with antihypertensive agents and uses thereof |
US20050182106A1 (en) * | 2002-07-11 | 2005-08-18 | Sankyo Company, Limited | Medicinal composition for mitigating blood lipid or lowering blood homocysteine |
US20040198789A1 (en) * | 2003-02-28 | 2004-10-07 | Recordati Ireland Limited | Lercanidipine/ARB/diuretic therapeutic combinations |
US20040248972A1 (en) * | 2003-05-16 | 2004-12-09 | Ambit Biosciences Corporation | Compounds and uses thereof |
US20050182125A1 (en) * | 2003-05-16 | 2005-08-18 | Ambit Biosciences Corporation | Pyrrole compounds and uses thereof |
AU2004247023A1 (en) * | 2003-05-16 | 2004-12-23 | Ambit Biosciences Corporation | Heterocyclic compounds and uses thereof |
US20050271717A1 (en) * | 2003-06-12 | 2005-12-08 | Alfred Berchielli | Pharmaceutical compositions of atorvastatin |
US20040253305A1 (en) * | 2003-06-12 | 2004-12-16 | Luner Paul E. | Pharmaceutical compositions of atorvastatin |
WO2005097191A2 (en) * | 2004-04-04 | 2005-10-20 | Sepracor Inc. | COMBINATIONS COMPRISING (S)- AMLODIPINE AND A HMG-CoA REDUCTASE INHIBITOR OR CHOLESTEROL ABSORPOTION INHIBITOR OR BOTH, AND METHODS FOR REDUCING HYPERTENSION |
ATE451925T1 (de) * | 2004-10-06 | 2010-01-15 | Eisai R&D Man Co Ltd | Medizinische zusammensetzung, verfahren zu ihrer herstellung und verfahren zur stabilisierung einer dihydropyridin-verbindung in einer medizinischen zusammensetzung |
US7816347B2 (en) | 2004-12-15 | 2010-10-19 | Solvay Pharmaceuticals Gmbh | Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous endothelin producing system and HMG CoA reductase inhibitors |
KR100582347B1 (ko) * | 2004-12-30 | 2006-05-22 | 한미약품 주식회사 | 3-하이드록시-3-메틸글루타릴 조효소 a 환원효소 억제제및 고혈압 치료제의 복합제제 및 그의 제조방법 |
PT2000137E (pt) | 2006-03-29 | 2016-02-17 | Kowa Co | Agente redutor de triglicerídeos e agente melhorador de hiperinsulinismo |
JP2008044870A (ja) * | 2006-08-11 | 2008-02-28 | Elmed Eisai Kk | 医薬組成物及びその製造方法 |
WO2008023869A1 (en) * | 2006-08-24 | 2008-02-28 | Hanall Pharmaceutical Co., Ltd. | Combined pharmeceutical formulation with controlled-release comprising dihydropyridine calcium channel blockers and hmg-coa reductase inhibitors |
PL2120878T3 (pl) | 2007-02-09 | 2015-01-30 | Alphapharm Pty Ltd | Postać dawkowania zawierająca dwa czynne składniki farmaceutyczne o różnych postaciach fizycznych |
US8048880B2 (en) * | 2007-05-03 | 2011-11-01 | Anthera Pharmaceuticals, Inc. | Treatment of cardiovascular disease and dyslipidemia using secretory phospholipase A2 (SPLA2) inhibitors and SPLA2 inhibitor combination therapies |
CA2686157A1 (en) * | 2007-05-03 | 2008-11-13 | Joaquim Trias | Treatment of cardiovascular disease and dyslipidemia using secretory phospholipase a2 (spla2) inhibitors and spla2 inhibitor combination therapies |
CN101433539A (zh) * | 2007-11-12 | 2009-05-20 | 北京瑞康医药技术有限公司 | 含有烟酸氨氯地平和他汀类药物的治疗组合物 |
CN101433538B (zh) * | 2007-11-12 | 2012-07-25 | 北京瑞康医药技术有限公司 | 含有氨氯地平和烟酸的治疗组合物 |
EP2161024A1 (de) | 2008-09-05 | 2010-03-10 | Universitätsklinikum Hamburg-Eppendorf | Kombinationspräparat zur Behandlung von Krebs |
IT1400309B1 (it) | 2010-05-10 | 2013-05-24 | Menarini Int Operations Lu Sa | Associazione di inibitori della xantina ossidasi e calcio antagonisti e loro uso. |
CN102755322B (zh) * | 2012-07-24 | 2013-12-11 | 兆科药业(广州)有限公司 | 一种乐卡地平和阿托伐他汀复方制剂 |
CN105758967B (zh) * | 2016-03-24 | 2017-10-27 | 中国药科大学 | 诊断区分冠状动脉粥样硬化和稳定型心绞痛的标志物群 |
CN110915354B (zh) * | 2019-12-05 | 2021-11-23 | 重庆市农业科学院 | 一种马铃薯种薯自动切块机 |
US11452690B1 (en) | 2021-01-27 | 2022-09-27 | ECI Pharmaceuticals, LLC | Oral liquid compositions comprising amlodipine besylate and methods of using the same |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5612114B2 (el) | 1974-06-07 | 1981-03-18 | ||
US4231938A (en) | 1979-06-15 | 1980-11-04 | Merck & Co., Inc. | Hypocholesteremic fermentation products and process of preparation |
US4444784A (en) | 1980-08-05 | 1984-04-24 | Merck & Co., Inc. | Antihypercholesterolemic compounds |
DK149080C (da) | 1980-06-06 | 1986-07-28 | Sankyo Co | Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre |
US4450171A (en) | 1980-08-05 | 1984-05-22 | Merck & Co., Inc. | Antihypercholesterolemic compounds |
DK161312C (da) * | 1982-03-11 | 1991-12-09 | Pfizer | Analogifremgangsmaade til fremstilling af 2-aminoalkoxymethyl-4-phenyl-6-methyl-1,4-dihydropyridin-3,5-dicarboxylsyreestere eller syreadditionssalte deraf samt phthalimidoderivater til anvendelse som udgangsmateriale ved fremgangsmaaden |
US4448784A (en) | 1982-04-12 | 1984-05-15 | Hoechst-Roussel Pharmaceuticals, Inc. | 1-(Aminoalkylphenyl and aminoalkylbenzyl)-indoles and indolines and analgesic method of use thereof |
US4739073A (en) | 1983-11-04 | 1988-04-19 | Sandoz Pharmaceuticals Corp. | Intermediates in the synthesis of indole analogs of mevalonolactone and derivatives thereof |
US5208225A (en) * | 1986-02-27 | 1993-05-04 | Warner-Lambert Company | Compositions containing fixed combinations |
GB8608335D0 (en) * | 1986-04-04 | 1986-05-08 | Pfizer Ltd | Pharmaceutically acceptable salts |
US4681893A (en) * | 1986-05-30 | 1987-07-21 | Warner-Lambert Company | Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis |
DE3807895A1 (de) | 1988-03-10 | 1989-09-21 | Knoll Ag | Erzeugnisse, enthaltend einen calciumantagonisten und einen lipidsenker |
US4804770A (en) | 1988-04-29 | 1989-02-14 | E. R. Squibb & Sons, Inc. | Process for preparing a keto-phosphonate intermediate useful in preparing HMG-CoA reductase inhibitors |
US5273985A (en) * | 1988-07-04 | 1993-12-28 | Eisai Co., Ltd. | Glycerin derivative and its pharmacological use |
EP0562643A3 (en) | 1988-10-13 | 1994-05-18 | Sandoz Ag | 7-substituted-hept-6-enoic and -heptanoic acids and derivatives thereof |
US4920123A (en) | 1988-10-21 | 1990-04-24 | Beyer Jr Karl H | Method for controlling and/or lowering serum triglyceride and/or cholesterol levels in mammals |
FI94339C (fi) * | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
US5622985A (en) | 1990-06-11 | 1997-04-22 | Bristol-Myers Squibb Company | Method for preventing a second heart attack employing an HMG CoA reductase inhibitor |
US5155120A (en) * | 1991-01-14 | 1992-10-13 | Pfizer Inc | Method for treating congestive heart failure |
US5208037A (en) * | 1991-04-22 | 1993-05-04 | Alza Corporation | Dosage forms comprising polymers comprising different molecular weights |
DE4309553A1 (de) | 1993-03-24 | 1994-09-29 | Bayer Ag | Verfahren zur Herstellung von 3R,5S-(+)-Natrium-erythro-(E)-7-(4-(4-flurophenyl)-2,6-diisopropyl-5-methoxymethyl-pyrid-3-yl)-3,5-dihydroxy-hept-6-enoat |
IN176897B (el) | 1993-10-29 | 1996-09-28 | Cadila Lab Ltd | |
US5385929A (en) | 1994-05-04 | 1995-01-31 | Warner-Lambert Company | [(Hydroxyphenylamino) carbonyl] pyrroles |
US5447922A (en) * | 1994-08-24 | 1995-09-05 | Bristol-Myers Squibb Company | α-phosphonosulfinic squalene synthetase inhibitors |
EP0738510A3 (fr) | 1995-04-20 | 2005-12-21 | L'oreal | Utilisation d'un inhibiteur d'HMG-coenzyme A-reductase pour lutter contre le vieillissement de la peau et pour traiter l'acné. Composition comprenant au moins un inhibiteur HMG-coenzyme A reductase et au moins un actif possédant des propriétes desquamantes |
US5798375A (en) * | 1995-07-03 | 1998-08-25 | Sankyo Company, Limited | Treatment of arteriosclerosis and xanthoma |
DE19539363A1 (de) | 1995-10-23 | 1997-04-24 | Basf Ag | Verfahren zur Herstellung von festen Arzneiformen |
GEP20001898B (en) * | 1995-11-02 | 2000-01-05 | Warner Lambert Co | Method and Pharmaceutical Composition for Regulating Lipid Concentration with Mam |
US6180660B1 (en) * | 1997-08-26 | 2001-01-30 | Merck & Co., Inc. | Cholesterol-lowering therapy |
GT199800126A (es) * | 1997-08-29 | 2000-01-29 | Terapia de combinacion. | |
GT199800127A (es) * | 1997-08-29 | 2000-02-01 | Combinaciones terapeuticas. | |
HN2000000050A (es) * | 1999-05-27 | 2001-02-02 | Pfizer Prod Inc | Sal mutua de amlodipino y atorvastatina |
CA2375372C (en) * | 1999-05-27 | 2007-01-09 | George Chang | Mutual prodrugs of amlodipine and atorvastatin |
US20030092745A1 (en) * | 2000-02-25 | 2003-05-15 | Pfizer Inc. | Combination therapy |
US7925624B2 (en) * | 2006-03-31 | 2011-04-12 | Amazon Technologies, Inc. | System and method for providing high availability data |
-
1998
- 1998-08-10 GT GT199800127A patent/GT199800127A/es unknown
- 1998-08-11 PA PA19988457101A patent/PA8457101A1/es unknown
- 1998-08-11 BR BR9812030-1A patent/BR9812030A/pt not_active Application Discontinuation
- 1998-08-11 NZ NZ537880A patent/NZ537880A/en not_active IP Right Cessation
- 1998-08-11 EP EP04013717A patent/EP1468682A1/en not_active Ceased
- 1998-08-11 DK DK98936587T patent/DK1003503T3/da active
- 1998-08-11 DE DE69826683T patent/DE69826683T2/de not_active Expired - Lifetime
- 1998-08-11 NZ NZ527158A patent/NZ527158A/en not_active IP Right Cessation
- 1998-08-11 JP JP2000508362A patent/JP2001514222A/ja active Pending
- 1998-08-11 DK DK04013754T patent/DK1491193T3/da active
- 1998-08-11 AT AT04013754T patent/ATE332689T1/de active
- 1998-08-11 ES ES04013754T patent/ES2266961T3/es not_active Expired - Lifetime
- 1998-08-11 AT AT98936587T patent/ATE277615T1/de active
- 1998-08-11 EA EA200000164A patent/EA003549B1/ru not_active IP Right Cessation
- 1998-08-11 IL IL13430398A patent/IL134303A0/xx unknown
- 1998-08-11 SI SI9830843T patent/SI1491193T1/sl unknown
- 1998-08-11 HU HU0003656A patent/HUP0003656A3/hu not_active Application Discontinuation
- 1998-08-11 ID IDW20000377A patent/ID23670A/id unknown
- 1998-08-11 KR KR1020007002144A patent/KR20010023498A/ko active Search and Examination
- 1998-08-11 PL PL339092A patent/PL192360B1/pl unknown
- 1998-08-11 PT PT04013754T patent/PT1491193E/pt unknown
- 1998-08-11 RS YUP-21/00A patent/RS50485B/sr unknown
- 1998-08-11 AU AU85548/98A patent/AU755636B2/en not_active Expired
- 1998-08-11 DE DE69835245T patent/DE69835245T2/de not_active Expired - Lifetime
- 1998-08-11 ME MEP-2008-790A patent/ME00545B/me unknown
- 1998-08-11 EP EP98936587A patent/EP1003503B1/en not_active Revoked
- 1998-08-11 SK SK204-2000A patent/SK284958B6/sk not_active IP Right Cessation
- 1998-08-11 TR TR2000/00561T patent/TR200000561T2/xx unknown
- 1998-08-11 WO PCT/IB1998/001225 patent/WO1999011259A1/en active IP Right Grant
- 1998-08-11 PT PT98936587T patent/PT1003503E/pt unknown
- 1998-08-11 CA CA002301732A patent/CA2301732C/en not_active Expired - Lifetime
- 1998-08-11 CN CNA200710110238XA patent/CN101062035A/zh active Pending
- 1998-08-11 CZ CZ20000511A patent/CZ301081B6/cs not_active IP Right Cessation
- 1998-08-11 CN CN98808460A patent/CN1268052A/zh active Pending
- 1998-08-11 ES ES98936587T patent/ES2227865T3/es not_active Expired - Lifetime
- 1998-08-11 EP EP04013754A patent/EP1491193B1/en not_active Expired - Lifetime
- 1998-08-11 SI SI9830696T patent/SI1003503T1/xx unknown
- 1998-08-18 HN HN1998000132A patent/HN1998000132A/es unknown
- 1998-08-24 PE PE1998000771A patent/PE107199A1/es not_active IP Right Cessation
- 1998-08-26 TN TNTNSN98156A patent/TNSN98156A1/fr unknown
- 1998-08-26 UY UY25157A patent/UY25157A1/es not_active IP Right Cessation
- 1998-08-26 DZ DZ980206A patent/DZ2596A1/xx active
- 1998-08-26 MA MA25227A patent/MA26535A1/fr unknown
- 1998-08-26 TW TW087114067A patent/TW592696B/zh not_active IP Right Cessation
- 1998-08-27 AR ARP980104288A patent/AR012269A1/es not_active Application Discontinuation
- 1998-08-27 MY MYPI98003935A patent/MY123993A/en unknown
- 1998-08-27 AP APAP/P/1998/001334A patent/AP1225A/en active
- 1998-08-27 CO CO98049138A patent/CO4970694A1/es unknown
- 1998-08-28 HR HR980473A patent/HRP980473B1/xx not_active IP Right Cessation
- 1998-08-28 ZA ZA9807844A patent/ZA987844B/xx unknown
- 1998-11-08 UA UA2000021173A patent/UA71897C2/uk unknown
-
2000
- 2000-01-14 IS IS5343A patent/IS2029B/is unknown
- 2000-01-31 IL IL134303A patent/IL134303A/en not_active IP Right Cessation
- 2000-02-18 OA OA1200000039A patent/OA11290A/en unknown
- 2000-02-22 BG BG104177A patent/BG64665B1/bg unknown
- 2000-02-25 US US09/512,914 patent/US6455574B1/en not_active Expired - Lifetime
- 2000-02-28 NO NO20000998A patent/NO320267B1/no not_active IP Right Cessation
-
2002
- 2002-08-07 US US10/214,058 patent/US20030008904A1/en active Pending
-
2003
- 2003-08-08 US US10/637,781 patent/US20040048906A1/en not_active Abandoned
-
2004
- 2004-03-19 JP JP2004080799A patent/JP2004210797A/ja active Pending
-
2006
- 2006-06-07 US US11/448,100 patent/US20060223865A1/en not_active Abandoned
- 2006-06-21 LU LU91253C patent/LU91253I2/fr unknown
- 2006-07-21 CY CY20061101012T patent/CY1105108T1/el unknown
- 2006-08-07 US US11/499,753 patent/US20060270717A1/en not_active Abandoned
-
2007
- 2007-01-25 CY CY200700003C patent/CY2007003I1/el unknown
- 2007-08-10 GE GEAP200710225A patent/GEP20084338B/en unknown
-
2009
- 2009-04-21 US US12/427,420 patent/US20090297598A1/en not_active Abandoned
- 2009-06-01 GE GEAP200911279A patent/GEP20104874B/en unknown
-
2010
- 2010-01-07 JP JP2010002257A patent/JP2010111693A/ja active Pending
- 2010-03-10 US US12/721,065 patent/US20100168187A1/en not_active Abandoned
-
2011
- 2011-04-21 US US13/091,622 patent/US20110201654A1/en not_active Abandoned
-
2012
- 2012-04-12 US US13/445,339 patent/US20120208854A1/en not_active Abandoned
-
2013
- 2013-01-17 US US13/743,897 patent/US20130131125A1/en not_active Abandoned
- 2013-10-09 US US14/049,286 patent/US20140039017A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1105108T1 (el) | Θepαπευτικοι συνδυασμοι που πepιλαμβανουν αμλοδιπινη και ατορβαστατινη | |
TR200000562T2 (tr) | Amlodifin ve bir statin bileşiği içeren bileşim terapisi | |
MY121008A (en) | Combination therapy comprising atorvastatin and an antihypertensive agent. | |
TR200103411T2 (tr) | Amlodipin ve atorvastatinin müşterek tuzu. | |
DE69838486D1 (de) | Hiv-1 tat oder deren derivate für prophylaktische und therapeutische impfung | |
TR200101470T2 (tr) | Farmasötik bileşim terkipleri. | |
UY27402A1 (es) | Composiciones farmacéuticas de amlodipina y atorvastatina | |
TR200103391T2 (tr) | Amlodipin ve atorvastatinin ön ilaçları. | |
ECSP982647A (es) | Terapia de combinacion | |
ECSP982646A (es) | Combinaciones terapeuticas | |
ECSP982645A (es) | Terapia de combinacion | |
ECSP003493A (es) | Profarmacos mutuos de amlodipino y atorvastatina |